Are Upatinib extended-release tablets a biological agent?

Upadacitinib extended-release tablets are not biologics, but a small molecule oral drug that is a selective Janus kinase 1 (JAK1) inhibitor. Its mechanism of action is mainly by inhibiting JAK1 and regulating the intracellular JAK-STAT signaling pathway, thereby reducing the production of a variety of pro-inflammatory cytokines, thereby alleviating inflammatory reactions and related symptoms.

Biological drugs are usually protein drugs extracted or synthesized from living cells through biotechnological means, often monoclonal antibodies or recombinant proteins. They are highly specific and selective against specific targets, such as cytokines, receptors or other immune system components. Since biologics are usually complex protein molecules, their preparation process is relatively complicated and usually requires injection, which carries high costs and risks of side effects.

Relatively speaking, small molecule drugs, such as upadatinib, have a simple structure and smaller molecular weight. They are usually administered orally and have better bioavailability and convenience. Small molecule drugs achieve their pharmacological effects by entering cells and interacting with intracellular targets. Such drugs are generally more economical to develop and produce and are easier to administer orally, increasing patient compliance.

Upapatinib is approved for the treatment of a variety of immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, moderate to severe atopic dermatitis, and ankylosing spondylitis. It can be given to patients orally and work quickly in the body to help patients relieve symptoms and improve their quality of life.

Although both upadatinib and biologics are used to treat similar diseases and may have some overlap in their anti-inflammatory effects, there are significant differences in drug structure, mechanism of action, and mode of administration. Therefore, upadatinib extended-release tablets should not be regarded as biologics, but an effective small molecule drug that provides a new treatment option for a large number of patients.